MedTrace Logo

HAT for the Treatment of Sepsis Associated With NASTI

NCT05157360 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-07-24

Study results available
· View outcomes & findings →

Summary

Evaluate the impact of HAT therapy versus placebo in the treatment of patients with an acute NSTI and sepsis.

Conditions

  • Necrotizing Soft Tissue Infection
  • Sepsis

Interventions

DRUG

HAT

hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT

DRUG

Placebo

normal saline solution

Sponsors & Collaborators

  • University of Kansas

    collaborator OTHER

  • Ascension Via Christi Hospitals Wichita, Inc.

    lead OTHER

Principal Investigators

  • Thomas Resch, M.D. · Surgeon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2023-05-16
Completion
2023-05-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05157360 on ClinicalTrials.gov